Skip to Content
PharmaceuticsPharmaceutics
  • Article
  • Open Access

2 April 2021

14 Pages

A Model-Informed Drug Development (MIDD) Approach for a Low Dose of Empagliflozin in Patients with Type 1 Diabetes

,
,
,
,
,
,
and
1
Metrum Research Group, Tariffville, CT 06081, USA
2
Boehringer Ingelheim International GmbH, 55216 Ingelheim, Germany
3
Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT 06877, USA
*
Author to whom correspondence should be addressed.

Abstract

In clinical trials, sodium-glucose co-transporter (SGLT) inhibitor use as adjunct to insulin therapy in type 1 diabetes (T1D) provides glucometabolic benefits while diabetic ketoacidosis risk is increased. The SGLT2 inhibitor empagliflozin was evaluated in two phase III trials: EASE-2 and EASE-3. A low, 2.5-mg dose was included in EASE-3 only. As the efficacy of higher empagliflozin doses (i.e., 10 and 25 mg) in T1D has been established in EASE-2 and EASE-3, a modeling and simulation approach was used to generate additional supportive evidence on efficacy for the 2.5-mg dose. We present the methodology behind the development and validation of two modeling and simulation frameworks: M-EASE-1, a semi-mechanistic model integrating information on insulin, glucose, and glycated hemoglobin; and M-EASE-2, a descriptive model informed by prior information. Both models were developed independently of data from EASE-3. Simulations based on these models assessed efficacy in untested clinical trial scenarios. In this manner, the models provide supportive evidence for efficacy of low-dose empagliflozin 2.5 mg in patients with T1D, illustrating how pharmacometric analyses can support efficacy assessments in the context of limited data.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.